Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03122197 · ClinicalTrials.gov registry record · Early Phase 1
Study of Letrozole in Recurrent Gliomas
A Early Phase 1 study, sponsored by University of Cincinnati.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 39
- Enrollment target
NCT03122197: Recruiting Early Phase 1 study, sponsored by University of Cincinnati.
NCT03122197 is a Early Phase 1 study that is actively recruiting participants, run by University of Cincinnati. The registered enrollment target is 39 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (26% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03122197, a Early Phase 1 study, is actively recruiting participants, sponsored by University of Cincinnati.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 39 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the ability of letrozole to penetrate the blood brain barrier and concentrate in gliomas.
Primary Outcome
Pharmacokinetic modeling will be used to determine the overall AUC in the tumor tissue to assess for letrozole penetration through blood brain barrier.
Interventions
- DRUG Temozolomide
- DRUG Letrozole Oral Tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2017-05-16 |
| Est. Completion | 2027-12 |
| Phase | Early Phase 1 |
What NCT03122197 shows while recruiting
NCT03122197 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 39 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (26% lower).
The record links to 0 conditions, and to 2 interventions - of which Temozolomide is the first listed.
NCT03122197 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03122197 about?
NCT03122197 is a clinical study titled "Study of Letrozole in Recurrent Gliomas". The purpose of this study is to determine the ability of letrozole to penetrate the blood brain barrier and concentrate in gliomas.
What is the current status of trial NCT03122197?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 39 participants. The study started on 2017-05-16. Estimated completion is 2027-12.
What interventions are being tested in trial NCT03122197?
The interventions under investigation include: Temozolomide (DRUG), Letrozole Oral Tablet (DRUG).
Who is sponsoring clinical trial NCT03122197?
This trial is sponsored by University of Cincinnati, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03122197's enrollment target sits among peer trials
39 689th of 2000 higher than 1,303 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03465592 · 39 participants · Phase 1
Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma
- NCT03961776 · 39 participants
Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems
- NCT04050280 · 39 participants · Phase 2
CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
- NCT04190862 · 39 participants · Phase 1
E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI